Immunovaccine Inc. of Halifax, Nova Scotia, recently licensed its patented vaccine delivery technology to Pfizer Animal Health. The New York-based company plans to develop enhanced cattle vaccines incorporating the technology.
Specific terms of the exclusive, worldwide license agreement were not disclosed. However, Immunovaccine reported that it will receive upfront signing fees in addition to subsequent milestone payments and royalties on any Immunovaccine-delivered vaccines developed by Pfizer Animal Health.
The strength of Immunovaccine’s platform lies in its ability to reduce the number of required doses and to significantly enhance antibody onset and duration, according to the company.
“We see global demand growing among beef and dairy producers for new vaccines that can be safely and easily administered,” said Juan Ramon Alaix, president of Pfizer Animal Health. “Pfizer looks forward to developing cattle vaccines incorporating Immunovaccine technology that will contribute to meeting this demand.”
Pfizer Animal Health reported that it is also licensing other Immunovaccine technology for the development of particular livestock vaccines.